203 results
F-3ASR
EX-1.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
with the standards of the American Institute of Certified Public Accountants (AICPA) or Public Company Accounting Oversight Board (PCAOB) by an independent
6-K
EX-99.4
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research
6-K
EX-99.2
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient
6-K
EX-99.1
SNY
Sanofi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business
6-K
EX-99.1
hzfer 3jtg9qj7g9
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.2
nn45z 07f0
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.1
wc1rqvhn8hwmn2ao
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.3
znoko
27 Sep 23
Current report (foreign)
6:06am
11-K
d982kmky
28 Jun 23
Annual report of employee stock purchases
2:32pm
11-K
st9tzb9wil8z0ohr1
28 Jun 23
Annual report of employee stock purchases
2:31pm
6-K
EX-99.2
9avcwviap7 v1
23 May 23
Current report (foreign)
1:01pm
6-K
EX-99.2
6j20dcvn ihxxzi
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
nxi4g 2um2
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.2
v0h5kj9ozy69d
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
t0rrzetvn
17 Oct 22
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
1:35pm
6-K
EX-99.1
29alhpzhm5k iet
3 Oct 22
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
11:24am
6-K
EX-99.3
pamm01fz
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.2
edhntalkahdi5 py
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.1
6ja3w5hkqmw dyvj
20 Jul 22
Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
12:38pm